|Bid||228,500.00 x 0|
|Ask||229,000.00 x 0|
|Day's range||224,500.00 - 231,000.00|
|52-week range||212,500.00 - 538,000.00|
|Beta (5Y monthly)||1.18|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||1,500.00 (0.66%)|
|Ex-dividend date||29 Dec 2020|
|1y target est||N/A|
YONGIN, South Korea, November 01, 2021--GC Pharma (006280.KS) today announced that the European Medicines Agency (EMA) granted orphan drug designation (ODD) to Hunterase ICV (intracerebroventricular, generic name: idursulfase-beta (recombinant)) for the treatment of mucopolysaccharidosis type II (Hunter syndrome) in the European Union.
YONGIN, South Korea, November 01, 2021--GC Pharma (formerly known as Green Cross Corporation) (KRX: 006280), a South Korean biopharmaceutical company, today announced unaudited consolidated financial results for the three months ended 1 November 2021.
YONGIN, South Korea, August 12, 2021--GC Pharma (006280.KS) today announced the approval of GreenGene F (Beroctocog alfa) [Recombinant Human Coagulation Factor VIII for injection] for the control and prophylaxis of bleeding episodes in individuals with haemophilia A in China by the National Medical Products Administration (NMPA). GreenGene F was initially approved by the Korean health authority in 2010 for control and prevention of bleeding episodes in patients with haemophilia A.